Nurix Therapeutics (NRIX) EPS (Weighted Average and Diluted): 2020-2025
Historic EPS (Weighted Average and Diluted) for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to -$1.03.
- Nurix Therapeutics' EPS (Weighted Average and Diluted) fell 53.73% to -$1.03 in Q3 2025 from the same period last year, while for Aug 2025 it was -$2.97, marking a year-over-year decrease of 2.06%. This contributed to the annual value of -$2.88 for FY2024, which is 8.68% down from last year.
- According to the latest figures from Q3 2025, Nurix Therapeutics' EPS (Weighted Average and Diluted) is -$1.03, which was down 98.08% from -$0.52 recorded in Q2 2025.
- Over the past 5 years, Nurix Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.45 during Q2 2023, and registered a low of -$1.03 during Q3 2025.
- Moreover, its 3-year median value for EPS (Weighted Average and Diluted) was -$0.71 (2024), whereas its average is -$0.71.
- Per our database at Business Quant, Nurix Therapeutics' EPS (Weighted Average and Diluted) plummeted by 60.32% in 2022 and then surged by 55.45% in 2023.
- Quarterly analysis of 5 years shows Nurix Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.85 in 2021, then fell by 1.18% to -$0.86 in 2022, then increased by 10.47% to -$0.77 in 2023, then grew by 2.60% to -$0.75 in 2024, then tumbled by 53.73% to -$1.03 in 2025.
- Its EPS (Weighted Average and Diluted) was -$1.03 in Q3 2025, compared to -$0.52 in Q2 2025 and -$0.67 in Q1 2025.